Once weekly Yes Pre-filled disposable pen Clear, colorless solution 24 months from the date of manufacture Subcutaneous injection FDA and EMA approved for obesity treatment Nausea, vomiting, diarrhea, abdominal pain, constipation GLP-1 Receptor Agonist Not for use in patients with a personal or family history of medullary thyroid carcinoma Wegovy Product Description Step into the prime league of obesity treatment with Wegovy Semaglutide 1 Mg Injection-an imposing, rare solution for adults striving for advanced weight management
Recession-Proof Demand In 2026, the #1 fitness trend is "Exercise for Weight Management." Unlike fad diets, medical weight loss is backed by pharmaceutical giants and healthcare systems
GLP-1RAs appear to offer a potential dual therapeutic advantage, simultaneously targeting metabolic dysfunction and immune-mediated inflammation, thereby representing a potentially promising strategy in the management of early-stage PsA early PsA, although robust clinical evidence in this setting is currently lacking
Weight loss is an off-label use that requires a private prescription at full price